ReviewJournal of bacteriology2025
Extracellular defense of bacteria against antimicrobial peptides.
Review in Journal of bacteriology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Interactions ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are short chains of amino acids naturally produced by all kingdoms of life, which exhibit broad-spectrum activity against bacteria, fungi, and viruses and thus play a crucial defense role in organisms. Unlike conventional antibiotics, AMPs are less prone to induce bacterial resistance since they can act on multiple targets, mainly affecting cell membranes. Thus, AMPs are considered promising antibiotic agents for medical applications. However, bacteria have developed different mechanisms to resist the action of AMPs, which operate at the extracellular, surface, and intracellular levels. Extracellular defense against AMPs is mediated by an arsenal of molecules or cell-derived particles or structures that are secreted and constitute the bacterial releasome. The bacterial releasome-associated factors can sequester, degrade, or chemically modify AMPs, thus providing individual and collective bacterial defense against AMPs. This minireview describes how diverse and impressive the releasome mechanisms mediating AMPs resistance are as a first line of defense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.